Clinical trials: Coronary Patient
Congestive Heart Failure
Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake
To confirm the tolerability of intravenous administration of OPC-61815 at 8 or 16 mg once daily for a maximum of 5 days to CHF patients with volume overload despite having received diuretics (injection) other than vasopressin…
- Trial name
- NCT03962101
- Testing
- OPC-61815 injection
- Where
- Japan
- Volunteers
- 45 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Acute Coronary Syndromes
Effect of rHDL on Atherosclerosis - Safety and Efficacy: THE ERASE TRIAL
Currently available therapies to treat Acute Coronary Syndromes(ACS) have several limitations including; the relatively long treatment duration required before apparent significant benefit; the inability to achieve reversal of…
- Trial name
- NCT00225719
- Testing
- rHDL
- Where
- Canada
- Volunteers
- 180 people
- Sponsor
- CSL Limited
Heart Failure
Real-world Dapagliflozin Experience in Patients With Heart Failure in United Kingdom.
Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages.
- Trial name
- EVOLUTION-HF (NCT05188144)
- Where
- 10 sites in United Kingdom
- Volunteers
- 237 people
- Sponsor
- AstraZeneca
Non-Ischemic Congestive Heart Failure
Safety and Efficacy of Adipose Derived Stem Cells for Non-Ischemic Congestive Heart Failure
The intent of this clinical study is to answer the questions: 1. Is the proposed treatment safe 2. Is treatment effective in improving the disease pathology of patients with Heart Disease as assessed by a series of measurements…
- Trial name
- NCT01502501
- Testing
- Harvesting and Implantation of Adipose-Derived Stem Cells (ASCs)
- Where
- Mexico
- Sponsor
- Ageless Regenerative Institute
Mitral Valve Insufficiency
Annular Reshaping of the Mitral Valve for Patients With Mitral Regurgitation Using the Millipede IRIS System
Multi center evaluation of the Millipede IRIS for treatment of clinically significant mitral regurgitation in subjects determined appropriate for mitral valve surgery.
- Trial name
- NCT02607527
- Testing
- Mitral Valve IRIS Ring
- Where
- 2 sites in Brazil, Paraguay
- Volunteers
- 21 people
- Sponsor
- Boston Scientific Corporation
Chronic Heart Failure, CKD Stage 3
Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System
The REFORM-HF study aims to test a new technology, AQUAPASS, designed to assist patients experiencing symptoms of fluid overload due to Heart Failure.
- Trial name
- REFORM-HF (NCT06360380)
- Testing
- AquaPass System
- Where
- 10 sites in United States, Israel
- Volunteers
- 40 people
- Sponsor
- AquaPass Medical Ltd.
Sinus Node Dysfunction
Allometric-Pace Study
The goal of this observational study is to improve quality of life in sinus node dysfunction patients by utilizing allometric lower rate pacing (or called personalized lower rate, PLR) in standard commercially available…
- Trial name
- NCT05766462
- Testing
- Pacemaker lower rate setting
- Where
- 3 sites in China
- Volunteers
- 73 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Atrial Fibrillation
Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (NVAF)
In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the NVAF indication, Daiichi-Sankyo Thailand proposed this non-interventional study (NIS) to gain insight into the safety…
- Trial name
- NCT03247569
- Testing
- Edoxaban
- Where
- 6 sites in Thailand
- Volunteers
- 300 people
- Sponsor
- Daiichi Sankyo (Thailand) Ltd., a Daiichi Sankyo Company
Angina Pectoris, Coronary Heart Disease
Evaluate the Efficacy and Safety of MUSK Pill on Coronary Microvascular Dysfunction
Objective to evaluate the effect of Shexiang Baoxin Pill on myocardial ischemia in patients with coronary microvascular dysfunction (non obstructive coronary heart disease) through a randomized, double-blind, placebo-controlled…
- Conditions
- Angina Pectoris, Coronary Heart Disease, X Syndrome, Angina, Non Obstructive Coronary Artery Disease
- Trial name
- NCT04984954
- Testing
- MUSK pill
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
Aortic Valve Disease
Post Market Clinical Follow-Up Study in Patients Treated With the On-X Ascending Aortic Prosthesis (AAP)
The ASCEND post-market clinical follow-up study is undertaken to evaluate safety and clinical performance of the On-X Ascending Aortic Prosthesis (AAP) used in surgical aortic valve replacement.
- Trial name
- ASCEND (NCT05082454)
- Testing
- Open repair
- Where
- 11 sites in United States, Germany and 3 more
- Volunteers
- 108 people
- Sponsor
- JOTEC GmbH
Tetralogy of Fallot
Assessment of Right Ventricular Volume in Tetralogy of Fallott (TOF) Patients
Assessment of Right Ventricular Volume using the VentriPoint Medical system in patients with Tetralogy of Fallot following repair; a comparison study to cMRI.
- Trial name
- VMS TOF (NCT01419756)
- Testing
- VentriPoint Medical System
- Where
- 6 sites in United States, Canada
- Volunteers
- 109 people
- Sponsor
- VentriPoint Diagnostics Ltd.
Heart Failure
Real-world Dapagliflozin Experience in Patients With Heart Failure in Greece
Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide. Despite advancements in treatment, a HF diagnosis still leads to significant morbidity and mortality.
- Trial name
- EVOLUTION-HF (NCT05635331)
- Where
- 16 sites in Greece
- Volunteers
- 257 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.
The primary objective of the study is to assess the diagnostic efficacy (specificity and sensitivity) of flurpiridaz F18 injection PET myocardial perfusion imaging (MPI) compared to single photon emission computed tomography…
- Trial name
- NCT01347710
- Testing
- Flurpiridaz F18, 99mTechnicium (sestamibi or tetrofosmin)
- Where
- 81 sites in United States, Canada and 2 more
- Volunteers
- 795 people
- Sponsor
- Lantheus Medical Imaging
Atrial Fibrillation (AF)
Evaluation of the Effectiveness and Safety of Remote Electrocardiographic Monitoring in Patients with Atrial Fibrillation Following Ablation Therapy
Background: Atrial fibrillation (AF) is the most common arrhythmia, significantly contributing to complications such as stroke, heart failure, dementia, and increased mortality.
- Trial name
- PREEMPT-AF (NCT06751459)
- Testing
- MEMO Patch 2 - 14-day Monitoring, MEMO Patch 2 - 1-day Monitoring, MEMO Link
- Where
- 7 sites in South Korea
- Volunteers
- 270 people
- Sponsor
- HUINNO Co., Ltd
Heart Failure
Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone
This study will be conducted in subjects with clinical diagnosis of worsening chronic heart failure and either type 2 diabetes mellitus (DM) with or without chronic kidney disease (CKD) or moderate CKD alone treated with…
- Trial name
- ARTS-HF Japan (NCT01955694)
- Testing
- BAY94-8862, Eplerenone
- Where
- 29 sites in Japan
- Volunteers
- 72 people
- Sponsor
- Bayer
Tricuspid Regurgitation (TR)
TraNsvenous TrIcuspid Valve ReplacemenT With LuX-Valve Plus System (TRINITY-US)
The LuX-Valve Plus System is intended for the treatment of patients with at least severe TR who are symptomatic and determined by a Heart Team not to be suitable for surgical treatment.
- Trial name
- NCT06568003
- Testing
- Transcatheter Tricuspid Valve Intervention
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Jenscare Innovation Inc.
Atrial Fibrillation, Vascular Risk
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)
The purpose of this study is to determine if the combination of clopidogrel 75mg once daily (od) plus aspirin 100mg daily (recommended dose) is better than aspirin alone (100mg daily recommended dose) for preventing vascular…
- Trial name
- NCT00249873
- Testing
- clopidogrel (SR25990C)
- Where
- 30 sites in United States, Argentina and 28 more
- Volunteers
- 7,554 people
- Sponsor
- Sanofi
Multi Vessel Coronary Artery Disease, STEMI
Assessing Microvascular Resistance Via IMR To Predict Cumulative Outcome in STEMI Patients Undergoing Primary PCI
The purpose of this study is to assess whether the Index of Microcirculatory Resistance (IMR) can be considered a prognostic predictor for the occurrence of events at one year of follow up after primary Percutaneous Coronary…
- Trial name
- AMICRO (NCT02325973)
- Testing
- PressureWire Certus guidewire
- Where
- 14 sites in Italy
- Volunteers
- 242 people
- Sponsor
- Abbott Medical Devices
Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study
The purpose of this clinical investigation is to evaluate how safe a less invasive cardiac surgery is using the AtriCure Bipolar System combined with a catheter ablation procedure in treating AF, and how effective this combined…
- Trial name
- DEEP (NCT01246466)
- Testing
- Hybrid: AtriCure Bipolar System & EP ablation procedure
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- AtriCure, Inc.
Acute Cardiac Ischemia
Evaluation of Patients in Chest Pain in the Emergency Room
The primary objective of this feasibility study is to determine whether it is possible to conduct a study of the ClearView scan among patients under evaluation for acute cardiovascular events, as well as give insight into the…
- Trial name
- EPIC-ER (NCT01476982)
- Testing
- ClearView Scan
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Epic Research & Diagnostics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.